D. Perrin

发表

Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited.

B. Hill, A. Kruczynski, D. Perrin, 2000, Critical reviews in oncology/hematology.

Inhibitors of the Ras signal transduction pathway as potential antitumour agents.

B. Hill, S. Halazy, D. Perrin, 1996, Journal of enzyme inhibition.

Expression in Yeast and Purification of Functional Recombinant Human Poly(ADP-RIBOSE)Polymerase(PARP). Comparative Pharmacological Profile with that of the Rat Enzyme

B. Hill, B. van Hille, D. Perrin, 2000, Journal of enzyme inhibition.

α-Fodrin (brain spectrin) immunocytochemical localization in rat vestibular hair cells

D. Aunis, D. Demêmes, D. Perrin, 1988, Neuroscience Letters.

Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine

B. Hill, S. Halazy, D. Bonnet, 1996 .

cAMP and Ca(2+)-mediated secretion in parotid acinar cells is associated with reversible changes in the organization of the cytoskeleton

H. Söling, K. Hanke, K. Möller, 1992, The Journal of cell biology.

BF2.649, A NON-IMIDAZOLE INVERSE AGONIST/ANTAGONIST AT THE HUMAN HISTAMINE H3 RECEPTOR: PRECLINICAL PHARMACOLOGY

H. Stark, F. Gbahou, V. Bertaina-Anglade, 2006 .

Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1

E. Moran, B. Hill, C. Etiévant, 2000, Anti-cancer drugs.

Anti-α-fodrin inhibits secretion from permeabilized chromaffin cells

O. K. Langley, D. Aunis, D. Perrin, 1987, Nature.

Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.

B. Hill, C. Etiévant, J. Barret, 2003, Biochemical pharmacology.

Convergent Functional Genomics of Oligodendrocyte Differentiation Identiﬁes Multiple Autoinhibitory Signaling Circuits (cid:1)

F. Zanoguera, C. Rommel, C. Salvat, 2009 .

F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.

B. Hill, B. van Hille, C. Etiévant, 2000, Biochemical pharmacology.

Overcoming the hurdle of fluorescent compounds in kinase screening: a case study.

A. Scheer, C. Frémaux, D. Perrin, 2006, Assay and drug development technologies.

Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis

Emilio Hirsch, Didier Leroy, C. Rommel, 2005, Nature Medicine.

Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.

C. Rommel, M. Camps, Jasna Klicic, 2006, Journal of medicinal chemistry.

Inhibition of the particle-associated RNA-dependent RNA polymerase activity of influenza viruses by chelating agents.

J. Oxford, D. Perrin, 1974, The Journal of general virology.

Purification stability and inhibition of the collagenase from Achromobacter iophagus

B. Keil, A. Lecroisey, D. Perrin, 1975, FEBS letters.

Lectin binding to serum 5'-nucleotidase and alkaline phosphatase in liver disease.

J. Harb, C. Massoubre, J. Orsonneau, 1990, Clinica chimica acta; international journal of clinical chemistry.

Assay Development and Screening of a Serine/Threonine Kinase in an On-Chip Mode Using Caliper Nanofluidics Technology

A. Scheer, Alexander Scheer, Dominique Perrin, 2006, Journal of biomolecular screening.

Structural basis for selective inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.

C. Gee, T. Alber, D. Swinnen, 2007, Structure.

Purkinje cells of rat and chicken cerebellum contain calreticulin (CaBP3)

B. Sönnichsen, Phu Nguyen-Van, H. Söling, 1991, FEBS letters.

Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro

B. Hill, C. Etiévant, J. Barret, 2004, Investigational New Drugs.

Reorganization of α-fodrin induced by stimulation in secretory cells

D. Aunis, Dominique Aunis, Dominique Perrin, 1985, Nature.

Tomorrow's anticancer agents: inhibitors of Ras farnesylation.

B. Hill, D. Perrin, 2000, EXS.

In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties

L. Cavarec, I. Chumakov, C. Giachetti, 2008, European Neuropsychopharmacology.

Chromaffin Granule Membrane‐F‐Actin Interactions and Spectrin‐Like Protein of Subcellular Organelles: A Possible Relationship

D. Aunis, D. Perrin, 1984, Journal of neurochemistry.

Protein-tyrosine Phosphatase H1 Controls Growth Hormone Receptor Signaling and Systemic Growth*

C. Rommel, C. Patrignani, M. Magnone, 2007, Journal of Biological Chemistry.

A Microfluidics-Based Mobility Shift Assay to Discover New Tyrosine Phosphatase Inhibitors

Wolfgang H. B. Sauer, A. Scheer, Alexander Scheer, 2006, Journal of biomolecular screening.

Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery

C. Frémaux, D. Perrin, A. Shutes, 2010, Expert opinion on drug discovery.

GLEPP1/Protein-tyrosine Phosphatase ϕ Inhibitors Block Chemotaxis in Vitro and in Vivo and Improve Murine Ulcerative Colitis

M. Shipp, C. Rommel, M. Camps, 2009, Journal of Biological Chemistry.

Alpha-fodrin in the adrenal gland: localization by immunoelectron microscopy.

O. K. Langley, D. Aunis, D. Perrin, 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Anti-alpha-fodrin inhibits secretion from permeabilized chromaffin cells.

O. K. Langley, D. Aunis, D. Perrin, 1987, Nature.

Tubulin‐ and Actin‐binding Proteins in Chromaffin Cells a

O. K. Langley, D. Aunis, M. Bader, 1987, Annals of the New York Academy of Sciences.

Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents

B. Hill, B. Hille, D. Perrin, 1998 .

Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases

Hong Zhang, C. Stroh, O. Bogatyrova, 2021, Lung Cancer.

Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases

F. Colpaert, B. Hill, C. Etiévant, 2000, British Journal of Cancer.

No evidence for calpain I involvement in fodrin rearrangements linked to regulated secretion

D. Perrin, Hans-Dieter Söling, 1992, FEBS Letters.

Differences in Sustained Cellular Effects of MET inhibitors Are Driven by Prolonged Target Engagement and Lysosomal Retention

J. Bomke, A. Eicher, B. Leuthner, 2022, Molecular Pharmacology.

Convergent Functional Genomics of Oligodendrocyte Differentiation Identifies Multiple Autoinhibitory Signaling Circuits

F. Zanoguera, C. Rommel, C. Salvat, 2009, Molecular and Cellular Biology.

A Homogeneous 384-Well High-Throughput Binding Assay for a TNF Receptor Using Alphascreen Technology

A. Scheer, C. Rossi, C. Frémaux, 2003, Journal of biomolecular screening.

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development

B. Hill, C. Etiévant, A. Kruczynski, 2002, British Journal of Cancer.

IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

L. Cascione, S. Napoli, F. Bertoni, 2023, Cancer research communications.

Enhanced cAMP production mediates the stimulatory action of pituitary adenylate cyclase activating polypeptide (PACAP) on in vitro catecholamine secretion from bovine adrenal chromaffin cells.

H. Söling, H. Jarry, W. Wuttke, 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

The stimulatory effect of pituitary adenylate cyclase activating polypeptide (PACAP) on LH release from rat pituitary cells in vitro does not involve calcium mobilization.

H. Söling, H. Jarry, W. Wuttke, 2009, Experimental and clinical endocrinology.

Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents.

B. Hill, B. van Hille, D. Perrin, 1998, Biochemical pharmacology.

Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.

B. Hill, C. Etiévant, J. Barret, 2000, Anticancer research.

Reorganization of alpha-fodrin induced by stimulation in secretory cells.

D. Aunis, D Aunis, D Perrin, 1985, Nature.

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103

B. Hill, B. van Hille, C. Etiévant, 2000, Cancer Chemotherapy and Pharmacology.